GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » EV-to-FCF

MAIA Biotechnology (MAIA Biotechnology) EV-to-FCF : -6.13 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MAIA Biotechnology's Enterprise Value is $81.47 Mil. MAIA Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.30 Mil. Therefore, MAIA Biotechnology's EV-to-FCF for today is -6.13.

The historical rank and industry rank for MAIA Biotechnology's EV-to-FCF or its related term are showing as below:

MAIA' s EV-to-FCF Range Over the Past 10 Years
Min: -6.31   Med: 0   Max: 0
Current: -6.13

MAIA's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs MAIA: -6.13

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), MAIA Biotechnology's stock price is $3.74. MAIA Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.580. Therefore, MAIA Biotechnology's PE Ratio for today is At Loss.


MAIA Biotechnology EV-to-FCF Historical Data

The historical data trend for MAIA Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology EV-to-FCF Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -2.27 -0.97

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -1.58 -2.01 -0.97 -2.78

Competitive Comparison of MAIA Biotechnology's EV-to-FCF

For the Biotechnology subindustry, MAIA Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's EV-to-FCF falls into.



MAIA Biotechnology EV-to-FCF Calculation

MAIA Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=81.471/-13.297
=-6.13

MAIA Biotechnology's current Enterprise Value is $81.47 Mil.
MAIA Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology  (AMEX:MAIA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MAIA Biotechnology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.74/-1.580
=At Loss

MAIA Biotechnology's share price for today is $3.74.
MAIA Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.580.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


MAIA Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology (MAIA Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606